Close Menu
TheKhaleejPost
    What's Hot
    Business

    Burjeel Holdings Receives Inaugural “AAA” MSCI Provisional ESG Rating, Outperforming GCC HealthCare Peers

    Business

    Falak Investments and Standard Chartered Elevate Female Tech Innovators in Saudi’s Latest Women In Tech Cohort

    Business

    PVH Reinforces Commitment to Enhanced Security in Solar Tracking Systems

    Important Pages:
    • Home
    • Privacy Policy
    • Terms & Conditions
    Facebook X (Twitter) Instagram Pinterest
    Facebook X (Twitter) Instagram Pinterest
    TheKhaleejPost
    • Home
    • Technology

      Future-focused: Swiss International Scientific School in Dubai expands IB Career-related Programme

      ArabyAds Talent introduces the next evolution of celebrity management and representation for MENA’s public figures

      Nokia, CST, ACES NH, along with Mobily and Zain launch industry-first 4.0 GHz spectrum sharing deployment using Neutral Host model in Saudi Arabia

      LG launches “Radio Optimism” campaign to spread “Life’s Good” through music

      EMR June 2025: 5G and FWA accelerating Gulf region’s digital ambitions

    • Business

      HPE and AMD celebrate launch of new ‘Saudi Made’ server at alfanar facility

      Rubrik unveils Agent Rewind for when AI agents go awry

      E&’s Monitoring-as-a-Service offers UAE businesses real-time infrastructure visibility and resilience

      Al Ansari Financial Services’ H1 2025 operating income increases by 13% to a record AED 638mln

      Bitget secures DIFC innovation license aligned with its MENA expansion strategy

    • Submit A Press Release
    TheKhaleejPost
    Home » Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature
    Business

    Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature

    Facebook Twitter Pinterest WhatsApp
    Share
    Facebook Twitter Pinterest WhatsApp

    Cairo – Sandoz the global leader in generic and biosimilar medicines, today announced the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone for the treatment of short stature to the Egyptian market, as part of its ongoing efforts to support Egypt’s Vision 2030. Local healthcare authorities remain committed to addressing various health challenges to enhance public health for current and future generations, and help build a healthier, more productive workforce.

    Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, underscored the importance of short stature treatment, with findings indicating that treatment with growth hormone significantly improved physical, social, psychological, and environmental quality of life¹.

    “In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH)² ³,” Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said.

    “Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions⁴ ⁵. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role⁶,” Dr Salem added.

    A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes⁷.

    “As noted, short stature affects children and adolescents, not only physically but also psychologically” Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, said.

    “Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results,” Dr. Tarif added.

    This new concentration is being made available, expanding treatment options in line with the latest global scientific standards. This will allow for a better patient response in the treatment journey by minimizing interruptions.  Securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care for children and reflects the Egyptian medical community’s commitment to delivering advanced treatment solutions for patients in need.

    “The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development,” Sameh Elbagoury, Sandoz Egypt Country Head, said.

    “Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15 mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature,” Elbagoury added.

    References

    1. Assessment of the effect of growth hormone therapy on quality of life among GHD and ISS children Available at https://journals.lww.com/ajpp/fulltext/2024/37030/assessment_of_the_effect_of_growth_hormone_therapy.8.aspx
    2. EDA Assessment Report for Biological Medicinal Product (Omnitrope) Available at https://www.edaegypt.gov.eg/media/r01pgvgf/par-omnitrope.pdf
    3. Omnitrope (Somatropin) injection, solution Available at https://www.guidelinecentral.com/drug/58d84ffa-4056-4e36-ad67-7bd4aef444a5/Omnitrope/
    4. Short Stature Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/short-stature
    5. Constitutional Growth Delay  Available at https://www.ncbi.nlm.nih.gov/books/NBK539780/
    6. Short Stature Available at https://www.ncbi.nlm.nih.gov/books/NBK556031/
    7. Prevalence of short stature and malnutrition among Egyptian primary school children and their coexistence with Anemia Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC7325115/

    DISCLAIMER

    This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

    ABOUT SANDOZ

    Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.  

    Disclaimer: The views expressed are those of the individuals and do not necessarily reflect the views of Sandoz.

    CONTACTS
    For Media Inquiries:
    Vantage Communications
    [email protected]

    Share. Facebook Twitter Pinterest WhatsApp
    Previous ArticleSimah Rating Agency assigns “BBB-” solicited national scale entity ratings to Innovest Real Estate Company
    Next Article Contact Insurance Brokerage joins forces with UN Global Compact to champion ESG and women in leadership

    Related Posts

    Business

    HPE and AMD celebrate launch of new ‘Saudi Made’ server at alfanar facility

    Business

    Rubrik unveils Agent Rewind for when AI agents go awry

    Business

    E&’s Monitoring-as-a-Service offers UAE businesses real-time infrastructure visibility and resilience

    Business

    Al Ansari Financial Services’ H1 2025 operating income increases by 13% to a record AED 638mln

    Business

    Bitget secures DIFC innovation license aligned with its MENA expansion strategy

    News

    Hamdan Centre for Giftedness and Innovation students excel in Cambridge University Pre-University Program

    Business

    Global Markets Stage at SBC Summit to Explore What’s Next for North America

    Business

    Etihad Rail to ‘open up new corridors for living, trade, and investment across the Emirates’

    Stay In Touch
    • Facebook
    • Twitter
    Top Picks
    Business

    Nisus Finance invests AED183mln in two properties, considers AED669mln more investment in Dubai’s real estate

    Dubai, UAE: Nisus Finance Investment Consultancy FZCO (NiFCO Dubai), a fully-owned subsidiary of Nisus Finance Services…

    Family Development Foundation extends Eid Al Fitr greetings to over 18,000 seniors and their families

    CPX Holding acquires spiderSilk to drive global cybersecurity expansion

    DP World Egypt marks historic week with landmark arrivals

    Korean Service Robot Companies to Showcase Innovative Technology in Dubai

    Stay ahead with TheKhaleejPost, your premier destination for breaking news, analysis, and in-depth coverage across the Gulf region and beyond. Discover diverse viewpoints, stay informed, and delve into the stories shaping our communities and world.

    Facebook X (Twitter)
    Categories
    • Business (423)
      • Career (1)
      • Management (5)
      • Startup (11)
    • Culture (77)
    • Entertainment (31)
      • Celebrity (3)
      • Movies (2)
      • TV Shows (1)
    • News (73)
    • Politics (12)
    • Technology (64)
      • Phones (2)
      • Science (2)
    • Videos (10)
    Our Picks
    Business

    Reload Logistics Unveils New Brand Identity and Major Expansions

    Technology

    MENA’s leading gaming and esports agency, Power League Gaming, launches “Flux” to help brands enter the fast growing space with lower cost solutions

    Business

    Pulse iD and Loylogic join forces to deliver smarter loyalty engagement

    © 2025 TheKhaleejPost.
    • Home
    • About Us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.